Eliot CPA - Tenax Therapeutics Interim Officer
| TENX Stock | USD 5.94 0.29 5.13% |
Insider
Eliot CPA is Interim Officer of Tenax Therapeutics
| Age | 66 |
| Address | 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 |
| Phone | (919) 855-2100 |
| Web | https://www.tenaxthera.com |
Tenax Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6609) % which means that it has lost $0.6609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1379) %, meaning that it created substantial loss on money invested by shareholders. Tenax Therapeutics' management efficiency ratios could be used to measure how well Tenax Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2024. Return On Capital Employed is likely to rise to -0.97 in 2024. At this time, Tenax Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2 M in 2024, whereas Non Current Assets Total are likely to drop 1,061 in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| James JD | Allarity Therapeutics | 55 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Frank Kondrad | Neurobo Pharmaceuticals | N/A | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| DDS MS | Aditxt Inc | 59 | |
| Jeffrey Millard | Ensysce Biosciences | 48 | |
| Tracy Rarick | Windtree Therapeutics | N/A | |
| Professor MD | Allarity Therapeutics | 67 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| John CPA | Unicycive Therapeutics | 62 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
| Geoffrey Birkett | Ensysce Biosciences | 61 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Diane Esq | Windtree Therapeutics | 55 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Ronald Dundore | Windtree Therapeutics | 69 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Marcel CPA | Altamira Therapeutics | 66 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.66 |
Tenax Therapeutics Leadership Team
Elected by the shareholders, the Tenax Therapeutics' board of directors comprises two types of representatives: Tenax Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tenax. The board's role is to monitor Tenax Therapeutics' management team and ensure that shareholders' interests are well served. Tenax Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tenax Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eliot CPA, Interim Officer | ||
| Nancy Hecox, Gen Affairs | ||
| Christopher Giordano, President CEO | ||
| Doug Randall, Executive VP of Commercial and Bus. Operations | ||
| Douglas Hay, Executive Vice President - Regulatory Affairs | ||
| Esq CPA, Interim Officer | ||
| Stuart MD, Chief Director |
Tenax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tenax Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 11.35 M | ||||
| Shares Outstanding | 3.41 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 47.95 % | ||||
| Number Of Shares Shorted | 120.87 K | ||||
| Price To Earning | (0.35) X | ||||
| Price To Book | 0.21 X | ||||
| EBITDA | (8.23 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.